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Abstract
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Cancer cells typically experience higher oxidative stress than normal cells, such that elevating prooxidant levels can trigger cancer cell death. Although pre-exposure to mild oxidative agents will
sensitize cancer cells to radiation, this pre-exposure may also activate the adaptive stress defense
system in normal cells. Ascorbic acid (AA) is a prototype redox modulator that when infused
intravenously appears to kill cancers without injury to normal tissues; however, the mechanisms
involved remain elusive. In this study, we show how AA kills cancer cells and sensitizes prostate
cancer to radiation therapy, while also conferring protection upon normal prostate epithelial cells
against radiation-induced injury. We found that the NF-κB transcription factor RelB is a pivotal
determinant in the differential radiosensitization effects of AA in prostate cancer cells and normal
prostate epithelial cells. Mechanistically, high ROS concentrations suppress RelB in cancer cells.
RelB suppression decreases expression of the sirtuin SIRT3 and the powerful antioxidant MnSOD,
which in turn increases oxidative and metabolic stresses in prostate cancer cells. In contrast, AA
enhances RelB expression in normal cells, improving antioxidant and metabolic defenses against
radiation injury. In addition to showing how RelB mediates the differential effects of AA on
cancer and normal tissue radiosensitivities, our work also provides a proof of concept for the
existence of redox modulators that can improve the efficacy of radiotherapy while protecting
against normal tissue injury in cancer settings.
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Introduction
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Prostate cancer is the most prevalent cancer in the United States and is the second leading
cause of cancer deaths in men (1). The predominant prostate cancer therapy, ionizing
radiation (IR), is used to treat more than 750,000 patients per year (2). Unfortunately, the
therapeutic efficacy of IR tends to decrease when cancer cells develop adaptive responses to
resist it. Even with modern conformal radiation therapy, biochemical failure occurs in
approximately 45% of patients with a locally confined disease (3). Additionally,
corresponding with the widespread use of high-dose IR to treat prostate cancer, the
incidence of radiation-related genitourinary toxicity has increased (4). Therefore, novel
therapeutic strategies to enhance both radiosensitization in cancer cells and radioprotection
in normal tissues are urgently needed.

Author Manuscript

Cancer cells are usually under higher oxidative stress than normal cells, and cellular redox
state is thought to be important to cell fate. The level of oxidative stress is also critical to
radiation response (5, 6). In addition to directly damaging DNA, IR can produce a large
amount of free radicals that cause cell death (5). Due to water radiolysis, IR causes excess
superoxide generation and allows leakage of electrons from the electron transport chain
(ETC), resulting in mitochondrial dysfunction (7). However, IR also tends to induce adaptive
reactive oxygen species (ROS) defense systems in cancers, which may lead to
radioresistance (8). While increasing radiation intensity can improve the ability to control
cancer growth, it presents the significant risks of increasing unwanted side effects, including
injury to normal tissues and reduced quality of life for cancer survivors. Thus, an attractive
radiation therapy would be one that exploits the intrinsic differences in the cellular redox
statuses of normal cells and cancer cells by selectively boosting ROS generation in cancer
cells to push them into oxidative stress overload while stimulating adaptive responses in
normal cells.

Author Manuscript

Ascorbic acid (AA), better known as vitamin C, has a somewhat controversial history as a
therapeutic drug for cancer treatment (9, 10). Emerging studies suggest that only
intraperitoneal or intravenous AA, and not orally administered AA, can reach
pharmacological concentrations that kill cancer (10, 11). However, although clinical trials of
AA have demonstrated the differences between administration routes and the safety of
intravenous AA (12, 13), there is still a lack in understanding the mechanisms by which AA
kills cancer cells. In general, the cytotoxicity induced by AA seems to be primarily mediated
by hydrogen peroxide (H2O2) generated in extracellular fluids (14). A recent elegant study
demonstrated that pharmacologic ascorbate enhances the cytotoxic effects of ionizing
radiation in pancreatic cancer cell lines, but not in nontumorigenic pancreatic ductal
epithelial cells because pancreatic cancer is sensitive to H2O2 (15). Thus, the cytotoxic effect
of AA may well be dependent on the local redox environment of the cancer cells.
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Mounting evidence suggests that ROS-mediated NF-κB activation is involved in the
radiation resistance of cancers (16). The NF-κB family includes NF-κB1 (p50/p105), NFκB2 (p52/p100), c-Rel, RelA (p65), and RelB. Recent studies have demonstrated that RelB
is uniquely expressed at a high level in prostate cancer with high Gleason scores, suggesting
that RelB plays an important role in the radioresistance of prostate cancer (17, 18). The
present study examined the effects of AA on cell survival and on the responses to radiation
of prostate cancer cells and normal prostate epithelial cells in vitro and in vivo. We found
that the intrinsic differences in the cellular redox state of normal and cancer cells account, in
part, for the differential effects of AA on the modulation of cellular redox status. The
expression of RelB in normal and cancer cells serves as a central regulator for their opposing
responses to radiotherapy.

Materials and Methods
Author Manuscript

Cell culture, cell transfection, and reagents

Author Manuscript

Human prostate cancer cell lines LNCaP and PC3, as well as normal human prostate
epithelial viral transformed PZ-HPV-7 (PZ) cells, were obtained from American Type
Culture Collection. These cell lines are routinely checked for morphological and growth
changes to probe for cross-contaminated or genetically drifted cells. All cell lines used have
been reauthenticated using the Short Tandem Repeat (STR) profiling service by ATCC.
Normal human epithelial cells (PrEC) were purchased from Lonza. The cells were cultured
and maintained in the manufacturer’s suggested media. Plasmid-cloned RelB cDNA and
siRNA for knocking down RelB were transfected into LNCaP and PC3 cells using a
Lipofectamine 2000 kit (Life Technologies) according to the manufacturer’s instructions.
AA (powder, USP/FCC grade, Fisher Chemical) was prepared as a 1 M stock solution in
sterile water, with sodium hydroxide added dropwise to adjust the pH to 7.0, as previously
described. H2O2 (Sigma) solutions were prepared freshly prior to application to the cells.
Treatment and cell survival analysis
Cell survival rates were quantified by colony survival and MTT assays. For colony survival
analyses, the cells were plated in 6-well plates at low densities and then treated with 0 to 1.0
mM AA for 2 h, which corresponds to the clinical time course of intravenous AA
administration (19). The formed colonies were washed with 1×PBS and stained with a
crystal violet dye for clonogenic assay. The surviving fraction was calculated as the ratio of
the number of colonies formed to the number of cells effectively plated.

Author Manuscript

For the MTT assay, cells were seeded in flat-bottomed 96-well plates, treated with 0 to 64
mM AA for 2 h, washed with fresh media, and incubated for 2 doubling times in the absence
of AA. Cell viability was detected by an MTT assay kit (Trevigen) following the standard
protocol. The IC50 for each cell line was calculated from a dose-response curve using
GraphPad Prism 6.0 software (GraphPad software). For evaluations of combination therapy,
PC3 and PZ cells were treated with AA, IR or a combination of the two. IR was performed
at 1 h after AA treatment by a 250 kV X-ray machine (Faxitron X-ray Corp.) with peak
energy of 120 kV, 0.05 mm Al filter, at a dose of 0 to 6 Gy. After total 2 h exposure to AA,
cells were incubated for 2 doubling times in the absence of AA and assessed by MTT assay.
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Combination Index (CI) values were calculated by CompuSyn 1.0 (CompuSyn) and the
effects of combined IR and AA treatment were evaluated according to the acknowledged
range of CI as published (20).
Animals

Author Manuscript

Four- to five-week-old male NCRNU (nu/nu athymic nude) mice were obtained from
Taconic (Hudson). For formation of xenograft tumors, 1.8×106 cells mixed in Matrigel (BD
Biosciences) were subcutaneously injected into the right flanks of the mice. Tumor volumes
were routinely measured and their sizes calculated on the basis of a protocol described
elsewhere (21). Animals with an average tumor size of 350 mm3 were randomized into 4
groups (n=10) and treatment commenced with intraperitoneal injection as follows: (i)
control, saline once daily; (ii) AA, 4.5 g/kg once daily; (iii) IR, 2 Gy once every other day;
(iv) IR+AA. The dosage of AA was determined by conversion of clinical trial data and with
reference to recent studies (22). For combination treatments, IR was performed at 1 h after
AA injection. After treatment, the mice were observed daily and humanely killed when the
tumor reached the maximum size of 1500 mm3. The tumor, prostate, and bladder tissues
were collected for protein and RNA analysis. All animal experimental procedures were
approved by the Institutional Animal Care and Use Committee of the University of
Kentucky (Lexington, KY), Approval Protocol No. 01077M2006.
Quantification of ROS level

Author Manuscript

An Amplex Red assay was used to quantify the levels of extracellular H2O2 after AA and IR
treatments. Briefly, cells were incubated with 50 μM Amplex Red reagent (ThermoFisher) at
37°C for 10 min. Fluorescence was detected at ex/em 550/590 nm using a Gemini XPS
Microplate Reader (Molecular Devices). The extracellular H2O2 level was calculated by a
standard curve and normalized to the cell number. MitoSox Red (ThermoFisher), a highly
selective mitochondrial superoxide indicator for live cells, was used to estimate the levels of
superoxide, and Mitotracker green FM (ThermoFisher) was used to locate mitochondria.
Rotenone (200 nM, Sigma), known to be a mitochondrial superoxide inducer, was used as a
positive control. To account for superoxide-specific fluorescence, the cells were pretreated
with 100 units/mL PEG-SOD (Sigma) for 24 h followed by the treatment. In brief, cells
were loaded with Mitotracker Green at 100 nM for 15 min followed by 5 μM MitoSox Red
for 10 min at 37°C and rinsed 3 times with HBSS before measuring fluorescence. Cellular
fluorescence intensity was detected using an Olympus IX71 fluorescence microscope and a
Gemini XPS Microplate Reader at ex/em 510/580 nm.
Catalase and MnSOD treatments

Author Manuscript

To further determine the specific high ROS level induced by AA and radiation, PC3 cells
were treated with various forms of catalase or MnSOD, including catalase (100u/mL), PEGCAT (200 U/mL), PEG-MnSOD (100 U/mL) or adenovirus MnSOD. Catalase, PEGcatalase and PEG-MnSOD were purchased from Sigma-Aldrich. For the adenovirus
experiments, viral vectors utilized included AdCMVEmpty (AdEmpty) and
AdCMVMnSOD (AdMnSOD), manufactured by Viraquest, Inc. (North Liberty, IA) as
previously described (23, 24). Approximately 106 PC3 cells were plated in a 100 mm2 tissue
culture dish and incubated with the adenovirus constructs for 24 h. Media were replaced
Cancer Res. Author manuscript; available in PMC 2018 March 15.
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with 5 mL of complete media for an additional 24 h before cells were harvested for MTT
assay or treated for ROS measurements.
Measurement of oxygen consumption rates, ATP, and lactate production
To determine whether AA changes mitochondrial function in cancer and normal cells, a
Seahorse Bioscience XF96 Extracellular Flux Analyzer was used to measure oxygen
consumption rates (OCR) after 2 h of treatment with 4 mM AA. The data were normalized
with protein levels and expressed as the OCR in pmol/min/μg protein. Cellular ATP
concentrations were measured using an ATP Assay kit (Biomedical Research Service
Center). Extracellular and intracellular lactate levels were measured by a Lactate Assay kit
(Biomedical Research Service Center). Data were normalized to the cell number, as
indicated in each figure.

Author Manuscript

Western blots
Lysates from homogenized cells and tumor tissues were electrophoresed on a 10–12% (w/v)
SDS-PAGE gel, transferred onto a nitrocellulose membrane, and subsequently incubated
with primary antibodies against RelA, RelB, Bcl-xl, Bax, or GAPDH from Santa Cruz
Biotech, or SIRT1 (Upstate Biotech), MnSOD (Upstate Biotech), SIRT3 (Cell Signaling), or
β-actin (Sigma). All secondary antibodies were obtained from Santa Cruz Biotech. The blots
were visualized using an enhanced chemiluminescence detection system (Amersham
Pharmacia Biotech).
Real-time PCR

Author Manuscript

mRNA was isolated from cells and tissues using a MagNA Pure Compact RNA Isolation Kit
(Roche) and reverse-transcribed using a Taqman reverse transcription kit (ThermoFisher)
according to the manufacturer’s instructions, and then analyzed using a LightCycler® 480
Real-Time PCR System (RT-PCR, Roche) with gene-specific primers. All primers were
purchased from Invitrogen. Primer sequences for human genes were as follows:

RELB 5′-cacttcctgcccaaccac-3′ (forward) and 5′-gacacggtgccagagaaga-3′
(reverse); Bcl-xl 5′-agccttggatccaggagaa-3′ (forward) and 5′gctgcattgttcccatagagt-3′ (reverse); SIRT3 5′-cttgctgcatgtggttgatt-3′ (forward) and
5′-cggtcaagctggcaaaag-3′ (reverse); β-actin 5′-ccaaccgcgagaagatga-3′ (forward)
and 5′-ccagaggcgtacagggatag-3′ (reverse).
Primer sequences for mouse genes were as follows:

Author Manuscript

RelB 5′-gtgacctctcttccctgtcact-3′ (forward) and 5′-tgtattcgtcgatgatttccaa-3′
(reverse); Sirt3 5′-tcctctgaaaccggatgg-3′ (forward) and 5′tcccacacagagggatatgg-3′ (reverse); β-actin 5′-ctggctcctagcaccatga-3′ (forward)
and 5′-acagtgaggccaagatggag-3′ (reverse).
NF-κB binding assay
Nuclear extracts from the treated and untreated PC3 and PZ cells were prepared by a nuclear
extract kit (Active Motif). Binding activities of RelA and RelB were measured using an
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ELISA-based TransAM NF-κB Family kit (Active Motif) according to the manufacturer’s
protocol.
Chromatin immunoprecipitation

Author Manuscript

A Pierce™ Agarose ChIP Kit (ThermoFisher) was used to study RelB-mediated
transcriptional regulation according to the manufacturer’s protocol. A potential RelB
binding site was predicted in the promoter region of the human SIRT3 gene based on a
search of the Ensembl genome database and a recent study (25). Briefly, chromatin was
pulled down using a RelB antibody (Santa Cruz Biotech), and a DNA fragment containing
an NF-κB element located in the SIRT3 promoter region was analyzed by quantitative PCR
(qPCR) with LightCycler® 480 SYBR Green I Master kit (Roche). PCR primer sequences
for SIRT3 were 5′-gaattatgaaatgagcacag-3′ (forward) and 5′-caggatagcaagaacgagca-3′
(reverse). Rabbit IgG antibody was used as a negative control. ChIP-qPCR data were
normalized by input preparation.
Intracellular Catalase, Gpx and MnSOD enzymatic assay
The activities of catalase and Gpx were measured by a Catalase- specific activity assay kit
(Abcam) and a Gpx Cellular activity assay Kit (Sigma) according to the manufacturers’
protocols, respectively. MnSOD activities were measured by the nitroblue tetrazoliumbathocuproin sulfonate reduction inhibition method. Sodium cyanide (2 mM) was used to
inhibit CuZnSOD activity as a previous study described (26).
Quantitative and statistical data analyses

Author Manuscript

Multiple independent experiments were conducted for each set of data presented. Image data
were quantified using the quantitative imaging software Image-pro Plus 6.0 (Media
Cybernetics). Toxicity comparisons of multiple groups were analyzed using ANOVA and a
post-hoc test. Data represent the mean ± SEM. Kaplan-Meier survival curves and the logrank test were performed for comparison of the survival curves in animal experiments.
Statistical significances of other experiments were analyzed using one-way ANOVA and
Tukey’s multiple comparison tests. All analyses were performed with IBM SPSS 21.0
software (Microsoft). Differences with an associated P <0.05 were considered to be
significant.

Results
AA enhances radiosensitivity in prostate cancer cells but protects normal cells from
radiotoxicity

Author Manuscript

To determine the cytotoxicity of AA in prostate cancer and normal cells, LNCaP, PC3,
PrEC, and PZ cells were plated for colony survival assays and MTT assays. As shown in
Fig. 1A and B, high doses of AA alone efficiently killed cancer cells but exerted no or
minimal effect on normal cells. Interestingly, AA appears to be more efficient in killing
aggressive prostate cancer PC3 cells than LNCaP cells. Based on a dose-effect curve, the
IC50 values for PC3, LNCaP, PrEC, and PZ cell lines were quantified as 3.96 mM, 12.81
mM, 36.56 mM, and 33.79 mM, respectively, indicating that AA has different cytotoxic
effects on prostate cancer and normal cells.
Cancer Res. Author manuscript; available in PMC 2018 March 15.
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To determine the capacity of AA to sensitize prostate cancer cells to IR, we used the
protocol for radiosensitization of PC3 cells described in our previous study (27), taking into
consideration the relative AA IC50 value in clinical application (28). The total dose of AA
was kept at 2 mM (for 1/2 IC50) or 4 mM (for the full IC50). Pretreatment with AA
significantly increased the radiosensitivity of PC3 cells in a dose-dependent manner within
an IR range of 0.5 to 6 Gy (Fig. 1C). Interestingly, pretreatment with AA resulted in the
opposite effect in PZ cells, indicating that AA actually protects normal cells against the
cytotoxicity induced by IR (Fig. 1C). To assess the combined effects of AA and IR, the CI
value for each dose was calculated by CompuSyn software based on the Chou-Talalay
method (20). A dose of 4 mM AA conformed to the Cl range description, in that it displayed
a synergistic effect on IR from 1 to 6 Gy in PC3 cells (Table S1). On the contrary, both doses
of AA in PZ cells displayed antagonistic effects on IR over a dose range of 0.5 to 6 Gy.
These results suggest that equivalent pharmacological doses of AA can exert different
radiosensitization effects in prostate cancer and normal cells.
AA differentially modulates cellular ROS levels in cancer and normal cells
To determine the effect of AA on redox homeostasis in cancer and normal cells, the levels of
ROS and mitochondrial superoxide anion were measured with and without AA treatment.
As shown in Fig. 2A, the basal level of extracellular H2O2 was slightly but significantly
higher in prostate cancer cells than in normal cells. In comparison to the result in PZ cells,
AA treatment induced a significant increase in ROS in prostate cancer cells, especially PC3
cells (Fig 2A). Pretreatment with PEG-Catalase or catalase obviously inhibited such
extracellular H2O2 increases and weakened toxicity of AA in PC3 cells (Fig. S1A and B).
These results are consistent with previous reports that AA produces H2O2 by oxidative
reaction with metal ions in extracellular fluid and exerts cytotoxic effects (14, 15).

Author Manuscript

To evaluate intracellular redox status, superoxide levels in mitochondria, the primary source
of cellular ROS, were quantified in cancer and normal cells. Mitotracker green staining with
negligible stimulated ROS was used to normalize MitoSox red to quantify mitochondrial
superoxide anion induced by AA with rotenone as a positive control. AA induced
superoxide generation in PC3 cells, but the effect was mitigated by adding PEG-SOD (Fig.
S1C). Consistent with the results for cytotoxicity in Fig. 1, AA increased IR-induced
superoxide generation in PC3 cells but decreased it in PZ cells (Fig. 2B). Increasing
endogenous MnSOD expression in PC3 cells clearly decreased superoxide, especially IRinduced superoxide generation after AA treatment (Fig S1D). These results suggest that AA
amplifies IR-induced cellular ROS level in cancer cells. They also suggest that AA
suppresses IR-induced ROS generation in normal cells.

Author Manuscript

AA differentially modulates mitochondrial function in cancer and normal cells
To test whether altering cellular redox status is associated with mitochondrial function, the
oxygen consumption rate (OCR) in the AA-treated cells was measured using a Seahorse
Bioscience XF96 OxygenFlux Analyzer. As shown in Fig. 3A, AA treatment decreased
basal, ATP-linked, and maximal OCR but not reserve capacity in PC3 cells. In contrast, AA
treatment increased the maximal OCR and reserve capacity of PZ cells. To test if such
effects modulate the energy production of cells, the cellular ATP and lactate levels were
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determined with and without treatment. As expected, pretreatment with AA significantly
diminished intracellular ATP when combined with IR, but increased both extracellular and
intracellular lactate production in PC3 cells (Fig. 3B, C, D). In contrast, combined AA and
IR treatment increased ATP production but decreased lactate concentrations in normal PZ
cells (Fig. 3B, C, D). These results suggest that AA-mediated alterations in cellular
oxidative and metabolic stresses play pivotal roles in the radiation response of both prostate
cancer and normal cells. Importantly, AA exacerbates mitochondrial dysfunction in cancer
cells, but alleviates radiation-induced mitochondrial dysfunction in normal cells.
AA inversely regulates RelB expression in cancer and normal cells

Author Manuscript

NF-κB signaling is involved in multiple biological processes responsive to ROS (29). The
best known activator of NF-κB is RelA, which is associated with radioresistance in many
types of cancer. Our previous findings demonstrate that RelB is also highly expressed in
prostate cancer cells and is a major contributor to radioresistance (18, 30). To probe which
member of the NF-κB family is affected by AA, we first determined whether AA regulates
the expression of RelA and RelB in prostate cancer and normal cells at the mRNA and
protein levels. While AA slightly increased RelA protein levels in both cancer and normal
cells, AA strongly down-regulated RelB protein and mRNA in cancer cells and up-regulated
RelB in normal cells (Fig. 4A). To further verify this finding, an NF-κB binding assay was
performed to confirm AA activation or suppression of RelA and RelB. As shown in Fig. 4B,
RelB binding activity was strongly suppressed in PC3 cells but apparently activated in PZ
cells after AA treatment alone. Importantly, pretreatment with AA significantly diminished
IR-induced RelB activation in PC3 cells. No significant effect of AA was observed on RelA
binding activity, but a small but significant increase was observed with combination
treatment in PZ cells.

Author Manuscript

To further confirm the transcription effect of RelB on its target genes, the NF-κB-regulated
genes Bcl-xL and Bax were quantified to verify the regulation of the NF-κB pathway by AA
in prostate cancer and normal cells. Consistently, AA down-regulated Bcl-xL but upregulated Bax in PC3 cells, while the reverse effect of AA was observed in PZ cells (Fig.
S2A). Finally, to confirm the role of RelB in AA-induced cell killing of prostate cancer cells,
the level of RelB was manipulated by either overexpression of RelB in LNCaP cells or
knockdown of RelB in PC3 cells. AA-mediated cytotoxicity was increased in RelB-silenced
PC3 cells but reduced in RelB-overexpressed LNCaP cells (Fig. 4C, Fig. S2A).
RelB acts as a central regulator in response to oxidative and metabolic stresses in cancer
cells

Author Manuscript

Generally, the radiosensitization we find in cancer cells is due to the oxidative and metabolic
stresses induced by AA. Since our data showed that RelB plays an important role in AAinduced cell killing of prostate cancer cells, it was necessary to verify the functions of RelB
in oxidative and metabolic stresses. As shown in Fig 5A, knockdown of RelB reduced basal
ATP production and increased intracellular lactate level. When treated with AA, IR or
combination treatment, RelB-silenced PC3 cells displayed more aggravated metabolic stress
compared to the control group (Fig 5A). The OCR data further confirmed the effect of
suppressing RelB on mitochondrial function in cancer cells, especially when treated with
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AA and IR (Fig 5B). To confirm the role of RelB in response to oxidative stress, the
activities of ROS related enzymes were evaluated in RelB-silenced PC3 cells. As shown in
Fig 5C, 5D knocking down RelB markedly weakened the ability of ROS elimination in
cancer cells which was revealed by the reduction of catalase, GPX and MnSOD activities.
These results confirm the role of RelB in oxidative and metabolic regulations. Furthermore,
they confirm that RelB may be a central regulator that adjudicates the differential effects of
AA in normal and cancer cells.
RelB transcriptionally regulates SIRT3 in response to AA treatment

Author Manuscript

SIRT3, a member of the sirtuin family of NAD+-dependent protein deacetylases, is known
to play a critical role in maintaining mitochondrial function, ROS response, and cell
proliferation, as well as in inducing radioresistance in cancers. Recently, a sequential action
of SIRT1-RelB-SIRT3 has been reported in sepsis (31), but the related mechanisms remain
to be fully elucidated. To probe the relationship of SIRT3 with RelB in AA-induced
cytotoxicity in cancer cells and the protective effect in normal cells, the levels of SIRT1 and
SIRT3 relative to RelB were quantified in PC3 and PZ cells. As shown in Fig. 6A, upregulation and down-regulation of SIRT3 correlated with RelB in the AA-treated cells, but
no significant changes were observed in SIRT1. Interestingly, MnSOD, a typical NF-κBregulated mitochondrial antioxidant enzyme, was suppressed in PC3 cells but enhanced in
PZ cells treated with AA (Fig. 6A).
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Manipulation of RelB expression in cancer cells altered SIRT3 levels, indicating that SIRT3
is regulated by RelB (Fig. 6B). Subsequently, RT-PCR showed that RelB transcriptionally
regulated SIRT3 in the AA-treated cells (Fig. 6C). Furthermore, chromatin was pulled down
by a RelB antibody, and a promoter region of the human SIRT3 gene containing a NF-κB
element was quantified by qPCR (Fig. 6D). The amount of the pulled down promoter
fragment was reduced by AA treatment in PC3 cells but increased in AA-treated PZ cells.
When combined with IR, AA consistently suppressed the activated RelB-SIRT3 signal in
cancer cells but further activated the RelB-SIRT3 signal in normal cells.
AA enhances radiosensitivity of prostate cancer in vivo

Author Manuscript

To further confirm our findings in vitro, a tumor-bearing mouse model was used to verify the
effect of AA on tumor growth. Mice were subcutaneously injected with PC3 cells followed
by AA and IR treatments. Mice were humanely killed and tumors as well as prostate and
bladder tissues were collected when the tumor volume reached 1500 mm3. The tumor
growth rate of each group shown in Fig. 7A demonstrates the efficacy of AA in sensitizing
prostate cancer to radiation therapy. There was a trend toward significance in the differences
between AA-treated and untreated mice. The time needed for the tumors in each group to
reach 1500 mm3 was independently analyzed (Fig. S3A).
mRNA and protein levels of RelB and its targets, SIRT3 and MnSOD, were quantified in the
extracted tumor tissues. Consistent with the results obtained in vitro, IR increased the levels
of RelB, SIRT3, and MnSOD, but AA eliminated the increases (Fig. 7B). In addition,
prostate and bladder tissues were used to probe whether AA activates a protective response
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against radiation injury in normal tissues. AA increased levels of RelB and SIRT3 mRNA in
normal prostate and bladder tissues (Fig. 7C).
Overall, AA enhances the radiosensitivity of prostate cancer cells but protects normal cells
from radiotoxicity through RelB-dependent transcriptional regulation, with consequences for
downstream target genes, such as SIRT3 and MnSOD, that lead to distinct responses to
radiation, as illustrated in a working model based on the results obtained to- date (Fig. 7D).

Discussion

Author Manuscript

The problems of the radioresistance of cancer tissues and the toxic side effects of IR in
normal tissues have been extensively investigated in both scientific and clinical settings.
However, traditional approaches have focused on ensuring that protecting normal tissues
from injury does not also reduce the therapeutic efficacy of radiation. Here, we demonstrate
that AA, a redox active agent, can enhance the therapeutic efficacy of radiation therapy
while simultaneously protecting normal tissues against the side effects of radiation therapy.
That AA enhances traditional radiotherapy and chemotherapy of cancer has been reported
since 1977 (14,15, 32–35). In the intervening decades, AA has been used to alleviate some
of the side effects of radiation therapy during cancer treatment (34, 36). A recent study by
Du et al. clearly shows the radiosensitization induced by pharmacological AA in pancreatic
cancer cells (15). These authors also observed that AA also potentially protects the
gastrointestinal tract from IR in vivo. Although it was not a major focus of the study, the Du
et al. observation is consistent with our finding that AA indeed protects normal prostate and
bladder tissues from IR.
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Elevated ROS levels, which are essential for tumorigenesis and metastasis, have been
observed in many types of cancer. High levels of ROS may reveal a specific vulnerability of
malignancy that can be used to selectively enhance cell death by further increasing the level
of cellular ROS. Here, we show that AA acts as a prooxidant at pharmacological doses and
differentially modulates cellular responses to ROS in normal and cancer cells. Our results
are consistent with previous studies demonstrating that the cytotoxicity induced by AA is
primarily mediated by H2O2 (14, 15, 19 and 22). However, the previous studies did not take
into consideration the respective distinct basal redox state of normal and cancer cells. Our
data suggest that AA causes an increase in ROS in prostate cancer cells that reaches a
threshold level of cell death but only slightly increases ROS in normal cells, resulting in an
induction of antioxidant and metabolic responses. These opposing effects of AA in normal
and cancer cells are mediated in part by the expression of RelB, a member of the alternative
pathway of the NF-κB family.
NF-κB is known to be an important ROS-responsive transcriptional factor involved in both
tumor progression and tumor resistance to treatment (16). Previous studies have indicated
that AA can inhibit NF-κB activation by preventing the degradation of IκB-α and nuclear
translocation of RelA (37, 38). Recent studies by our laboratory and others have
demonstrated that RelB contributes to radioresistance of prostate cancer cells by sustaining
NF-κB activation (17, 18). The present study further establishes the role of RelB as a critical
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redox signaling sensor that regulates its downstream target genes in response to AA, leading
to the observed opposing radiation responses in prostate cancer and normal cells. Repression
of IR-induced RelB activation in cancer cells results in diminished oxidative defense
capacity and subsequently enhances radiosensitivity through mitochondrial dysfunction. On
the contrary, up-regulation of RelB serves as a major mechanism by which AA protects
normal tissues against radiotoxicity, through up-regulation of antioxidant enzymes and the
mitochondrial function of scavenging ROS. RelA has been reported to be involved in RelB
transcriptional activation (39); further studies will be needed to determine whether and how
RelA participates in a meaningful change of RelB as it relates to AA.
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Recently, metabolic alterations in cancer cells due to AA-induced oxidative stress have been
the subject of intense investigation (15, 40). Although a high rate of aerobic glycolysis in
tumors, known as the Warburg effect, has been observed in various types of cancer, cancers
have functional mitochondria, and mitochondrial respiration is necessary for cancer cell
proliferation and resistance to therapy (41, 42). The present study shows that the
mitochondria in prostate cancer cells become dysfunctional, with down-regulated MnSOD,
after AA treatment. As a MnSOD transcriptional regulator, RelB modulation by AA leads to
the suppression and induction of MnSOD in cancer and normal cells, respectively.

Author Manuscript

Sirtuins are NAD+-dependent histone deacetylases in mammalian cells and are involved in
an array of critical cellular functions (43–46). Of the seven human sirtuins, SIRT3 is the best
characterized in its regulation of many aspects of mitochondrial function. Physiologically,
SIRT3 interacts with subunits of complexes I and II of the ETC to improve mitochondrial
respiration (47). SIRT3 also deacetylates and activates MnSOD to maintain the antioxidant
defense system in cells (48). A recent study described the expression of SIRT3 as a
sequential action of the SIRT1-RelB axis in a sepsis model (31). The present study suggests
that the RelB-SIRT3 signaling axis may play a critical role in AA treatment independent of
SIRT1 levels. Our results demonstrate that RelB regulates SIRT3 expression through binding
to its promoter region. Repression of RelB-activated SIRT3 transcription by AA aggravates
metabolic stress in cancer cells. In contrast, up-regulation of SIRT3 improves the ability of
mitochondria to defend against metabolic stresses in normal cells. These results suggest that
RelB may be a unique target for treatment of radiation-resistant prostate cancer.

Author Manuscript

Considering the unsatisfactory results of clinical trials of high doses of oral AA, and the
reported successes of high doses of intravenous ascorbate (49, 50), the complexity of the
mechanisms involved in AA treatment deserves further investigation. The present study
indicates a promising anticancer effect of AA that is dependent on cell properties such as the
basal redox state of the cancer and normal cells. The present study also reveals celldependent ROS generation in AA treatment and identifies the RelB-SIRT3-MnSOD axis as
a critical contributor to AA-induced radiosensitization of cancer cells and radioprotection of
normal cells (Fig. 7D). Thus, while additional mechanistic studies are needed to fully
understand the biological function of AA, we anticipate that other redox-based anticancer
therapeutics with protective properties against cytotoxic therapy will be discovered and that
they will have a significant impact on the care of cancer patients.
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The effect of AA on proliferation and radiosensitivity of prostate cancer and normal cells. A,
Two prostate cancer cell lines (PC3 and LNCaP) and one prostate epithelial cell line (PZ)
were treated with different concentrations of AA. Cell survival fraction was determined by
colony survival analysis. *, # P<0.001 comparing PZ cells to PC3 (*) and LNCaP (#) cells,
respectively. @ P<0.001 comparing LNCaP and PC3 cells. B, Two prostate cancer cell lines
(PC3 and LNCaP) and two prostate epithelial cell lines (PZ and PrEC) were treated with
different concentrations of AA. Cell survival fraction was determined by MTT assay. IC50
for each cell line was calculated based on the dose-response curve. *, #, & P<0.001
comparing PC3 cells to PZ (*), LNCaP (#) and PrEC (&) cells, respectively. @, $ P<0.001
comparing LNCaP cells to PZ (@) and PrEC ($) cells, respectively. C, Prostate cancer PC3
cells and prostate epithelial PZ cells were treated with IR and AA at indicated doses. Cell
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survival fraction was determined by MTT assay. *, # P<0.001 comparing IR group to IR
+2mM (#) and IR+4mM (*) groups, respectively. @ P<0.001 comparing IR+2mM and IR
+4mM groups. All the analyses were performed using linear regression models and
Likelihood ratio tests with Bonferroni correction.
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The effect of AA on redox homeostasis in prostate cancer and normal cells. A, Prostate
cancer and normal epithelial cells were treated with AA and then incubated with Amplex
Red. The extracellular H2O2 concentration was calculated by a standard curve and
normalized to the cell number. B, Concentrations of mitochondrial superoxide in PC3 and
PZ cells were measured by MitoSox Red after treatment with AA and IR as indicated.
Cellular fluorescence intensity was detected by fluorescence microscopy and a fluorescence
microplate reader. Mitochondria were visualized by staining with Mitotracker Green.
Microplate readings were normalized by protein levels. n.s, no significance detected. All the
analyses were performed using one-way ANOVA with post-hoc Tukey HSD test.
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The effect of AA on metabolic homeostasis in prostate cancer and normal cells. A, After AA
treatment, OCR in PC3 and PZ cells was measured by a Seahorse Bioscience XF96
OxygenFlux Analyzer. B, Intracellular ATP levels were measured after treatment with AA
and IR at the indicated doses. C and D, Extracellular and intracellular lactate levels. Twotailed Student’s t test was performed for comparisons of treated groups to control groups in
OCR test. One-way ANOVA with post-hoc Tukey HSD test was performed for comparisons
of multiple groups in cells. n.s. represents non-statistical significance.
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Figure 4.
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Differential regulation of RelB by AA in prostate cancer and normal cells. A, After AA
treatment, the expression levels of RelA and RelB were quantified by western blots and RTPCR. B, Nuclear extracts from the treated and untreated cells were subjected to the NF-κB
binding assay kit. Binding activities of RelA and RelB were determined by ELISA analysis.
C, RelB was overexpressed in LNCaP cells and silenced in PC3 cells by cell transfection,
and the cells were treated with different concentrations of AA. Cell survival fraction was
determined by MTT assay. * P<0.001 comparing LNCaP-RelB and LNCaP-Vector cells; #
P<0.001 comparing PC3-siRelB and PC3-Vector cells based on Linear regression models
and Likelihood ratio tests with Bonferroni correction. Other data were analyzed using oneway ANOVA with post-hoc Tukey HSD test.
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The regulation of RelB on redox and metabolic homeostasis. A, Intracellular ATP levels,
extracellular and intracellular lactate levels were measured after treatment with AA and IR at
the indicated doses in PC3 and in RelB-silenced PC3 cells. B, After AA and IR treatment,
OCR in PC3 and in RelB-silenced PC3 cells was measured by a Seahorse Bioscience XF96
OxygenFlux Analyzer. C, The level of cellular ROS was estimated by the ratio of
H2DCFDA to Carboxy-DCFDA. PEG-Catalase was used as a control to remove ROS
generated by AA. D, Catalase activity, Gpx activity and MnSOD activity were measured
after treatment with AA and IR in PC3 and in RelB-silenced PC3 cells. Two-tailed Student’s
t test was performed for comparisons of RelB- silenced group to control group.
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Figure 6.
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Modulation of SIRT3 due to AA-mediated RelB regulation. A, After AA treatment, the
expression of SIRT1, SIRT3, RelB, and MnSOD in PC3 and PZ cells was measured by
western blots. B, Protein levels of SIRT1 and SIRT3 after manipulation of RelB expression
in LNCaP and PC3 cells were determined by western blots. C, After AA treatment, mRNA
levels of SIRT3 in PC3 cells and PZ cells were determined by RT-PCR. D, Protein–DNA
complexes were extracted from the AA-treated or untreated PC3 and PZ cells and then
immunoprecipitated using a RelB antibody. The SIRT3 promoter fragment containing a NFκB element was amplified by q-PCR with specific primers, which were normalized by their
input controls containing relevant unprecipitated chromatin. E, After AA and radiation
treatment, the expression of RelB-SIRT3 in PC3 and PZ cells was measured by western
blots. One-way ANOVA with post-hoc Tukey HSD test was performed for comparison of
multiple groups in cells.
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AA-mediated radiosensitization of prostate cancer cells in vivo. A, Prostate cancer PC3 cells
were injected into the flanks of nude male mice and the formed tumors were treated with
AA and IR as indicated. Tumor volume was measured and tumor growth rate was calculated.
Kaplan-Meier survival curves and the log-rank test were performed for comparison of the
survival curves. B, The levels of RelB, SIRT3, and MnSOD in tumor tissue were measured
by western blots and RT-PCR. C, mRNA levels of RelB and SIRT3 in prostate and bladder
tissues were quantified by RT-PCR. D, A proposed mechanistic model for the AA-mediated
differential response to radiation in prostate cancer and normal cells. AA sensitizes cancer
cells to radiation by down-regulating RelB-SIRT3 signal, which in turn aggravates oxidative
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and metabolic stresses. In contrast, in normal prostate epithelial cells, H2O2 generated from
the redox reaction of AA up-regulates RelB, leading to increased SIRT3 levels, which
enhances cellular stress defense systems. Kaplan-Meier survival curves and the log-rank test
were performed for comparison of the survival curves in animal experiments. Other data
were analyzed using one-way ANOVA with post-hoc Tukey HSD test.
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